Home › Research › Risk genes beyond APOE
Triazole Hybrids for Alzheimer's Disease: Multitarget Potential and SAR Insights
Ankush Chauhan, Deepika Paliwal, Aman Thakur, Niranjan Kaushik, Rakesh Sahu, Avinash Jha, Hashim Chaudhary. ChemistrySelect, 2026-07-01
Topic: Amyloid, tau and blood-test diagnosis
ABSTRACT Alzheimer's disease (AD) is a degenerative neurological disorder characterized by loss of memory, cognitive decline, and differences in behavior that mainly affects the elderly. The multifactorial etiology of AD includes the aggregation of amyloid‐β, tau hyperphosphorylation, oxidative stress, cholinergic dysfunction, and neurotransmitter imbalances resulting from monoamine oxidase activity. Current pharmacological therapies are mainly symptomatic relief, highlighting the need for multitarget‐directed ligands. Triazole derivatives, known as nitrogen‐containing heterocyclic compounds, are gaining attention as viable therapeutic agents in modern drug design because of their chemical stability, possibly favorable bioavailability, and their ability to participate in hydrogen bonds and π–π interactions in the active sites of all the enzymes. This review will attempt to highlight the most recent advancements in triazole‐based analogues that target key enzymes involved in AD, including acetylcholinesterase, butyrylcholinesterase, MAO, and β‐site amyloid precursor protein cleaving enzyme‐1. Most notable structure–activity relationship studies have demonstrated that triazole hybrids that have electron‐donating, halogen, or methoxy substituents exhibit marked inhibition and perceived neuroprotective activity. These findings support the use of triazole scaffolds as a unique and versatile framework for developing multifunctional anti‐Alzheimer agents with perceived disease‐modifying activity.
Key findings
- Most notable structure–activity relationship studies have demonstrated that triazole hybrids that have electron‐donating, halogen, or methoxy substituents exhibit marked inhibition and perceived neuroprotective activity.
- These findings support the use of triazole scaffolds as a unique and versatile framework for developing multifunctional anti‐Alzheimer agents with perceived disease‐modifying activity.
Why it matters
This review discusses triazole-based compounds that inhibit acetylcholinesterase, butyrylcholinesterase, MAO and BACE1, with some structure-activity studies showing marked inhibition and perceived neuroprotective activity. It is a chemistry review and does not report clinical benefit in patients.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 27/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 26 of the 96 points we could judge it on, which is 27 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (ChemistrySelect) |
| Journal's citation record | 1 / 4 | ChemistrySelect: journal h-index 82 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Hashim Chaudhary holds only 1 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | Sharda University: institution h-index 162 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 26 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 26 of the 96 points we could judge it on is 27 out of 100. |
| Total | 27 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
APA 7th
Chauhan, A., Paliwal, D., Thakur, A., Kaushik, N., Sahu, R., Jha, A., et al. (2026). Triazole Hybrids for Alzheimer's Disease: Multitarget Potential and SAR Insights. ChemistrySelect. https://doi.org/10.1002/slct.73763
Vancouver
Chauhan A, Paliwal D, Thakur A, Kaushik N, Sahu R, Jha A, et al. Triazole Hybrids for Alzheimer's Disease: Multitarget Potential and SAR Insights. ChemistrySelect. 2026. doi:10.1002/slct.73763.
BibTeX
@article{chauhan2026-a7800f34,
author = {Chauhan, Ankush and Paliwal, Deepika and Thakur, Aman and Kaushik, Niranjan and Sahu, Rakesh and Jha, Avinash and Chaudhary, Hashim},
title = {{Triazole Hybrids for Alzheimer's Disease: Multitarget Potential and SAR Insights}},
journal = {ChemistrySelect},
year = {2026},
doi = {10.1002/slct.73763},
url = {https://doi.org/10.1002/slct.73763}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.
Related studies in Risk genes beyond APOE
Also tagged “double-blind”
783 studies in the library carry the topic tag “double-blind”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.